# Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

> **NCT00002556** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 312 (actual)

## Conditions studied

- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** vincristine sulfate
- **DRUG:** carmustine
- **DRUG:** melphalan
- **DRUG:** cyclophosphamide
- **DRUG:** prednisone
- **BIOLOGICAL:** recombinant interferon alfa-2b
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00002556
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-07
- **Primary completion:** 2006-01
- **Final completion:** —
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2013-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002556, "Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00002556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*